Kontafarma China Holdings Ltd (1312) Stock Price & Analysis

0 Followers

1312 Stock Chart & Stats

HK$0.03HK$0.00(0.00%)

At close: Nov 11 4:00 PM GMT+8

Day’s Range: HKD 0.02 - HKD 0.03
52-Week Range: HKD 0.02 - HKD 0.04
Previous Close: HKD 0.03
Volume: N/A
Average Volume (3M): 148.20K
Market Cap: HKD 156.20M
Enterprise Value: HKD 186.41M
Total Cash (Recent Filing): HKD 67.62M
Total Debt (Recent Filing): HKD 189.76M
Price to Earnings (P/E): ―
Beta: 0.31
Next Earnings: Apr 01, 2027 (Est.)
EPS Estimate: N/A
Last Dividend Ex-Date: May 27, 2013
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Strong Gross Margins

Consistently high gross margins indicate that the company retains meaningful economics after direct costs, supported by pricing or product mix. This provides a foundation for future operating improvement, although the benefit will depend on whether overhead and other expenses can be controlled.

Improving Cash Generation

Positive operating and free cash flow over the latest three years, together with a strong 2025 improvement, gives the company more internally generated funding for operations and investment. This is a durable support if cash conversion remains positive despite reported losses.

Lower Leverage

The substantial reduction in debt-to-equity lowers balance-sheet pressure and improves financial flexibility relative to earlier years. A less leveraged capital structure can reduce solvency risk and leave more capacity to manage ongoing losses or fund operations without relying as heavily on new borrowing.

Bears Say

Persistent Operating Losses

Negative EBIT and EBITDA show that strong gross margins are not translating into operating profitability. If heavy operating costs, charges, or weak operating leverage persist, the company may struggle to convert sales into sustainable earnings and may remain dependent on cash reserves or financing.

Equity Erosion And Weak Returns

A sharp negative return on equity indicates that shareholder capital is currently producing substantial losses rather than compounding value. The reported decline in equity further suggests that continued losses could weaken the capital base, reducing resilience and limiting long-term reinvestment capacity.

Unreliable Cash-to-Earnings Conversion

Recent cash generation is encouraging but has not yet been validated by consistent profitability or a stable history. The mismatch between positive cash flow and widening losses, alongside earlier negative free cash flow, makes the durability and quality of current cash conversion uncertain.

Kontafarma China Holdings Ltd News

Kontafarma China Wins Second Waiver on Delayed Lease Circular

The latest announcement is out from Kontafarma China Holdings Ltd ( ($HK:1312) ). Kontafarma China Holdings Limited has received a second waiver from the Hong Kong Stock Exchange allowing a

1M ago1312

Kontafarma Moves to Liquidate Loss-Making Singapore Fitness Subsidiaries

Kontafarma China Holdings Ltd ( ($HK:1312) ) just unveiled an announcement. Kontafarma China Holdings Ltd has disclosed that its indirect Singapore subsidiaries True Fitness Pte. Ltd. and True Yoga Pte.

2M ago1312

Kontafarma China Seeks Second Waiver as Lease Circular Faces Further Delay

Kontafarma China Holdings Ltd ( ($HK:1312) ) has issued an announcement. Kontafarma China Holdings, a Cayman Islands-incorporated company listed in Hong Kong, operates fitness and yoga centres and manages significant

2M ago1312

Kontafarma China Narrows Interim Loss Despite Revenue Decline

Kontafarma China Holdings Ltd ( ($HK:1312) ) has issued an update. Kontafarma China Holdings reported unaudited interim results for the six months ended June 30, 2026, showing revenue of HK$383.3

2M ago1312

Kontafarma Reshapes Top Management With New President and Executive Director

The latest announcement is out from Kontafarma China Holdings Ltd ( ($HK:1312) ). Kontafarma China Holdings Ltd has announced an internal reshuffle in its senior management, with chairman and executive

2M ago1312

Kontafarma China Refines Board and Committee Structure for Stronger Governance

Kontafarma China Holdings Ltd ( ($HK:1312) ) has provided an update. Kontafarma China Holdings Ltd has updated its board composition effective 17 August 2026, confirming a seven-member Board comprising four

2M ago1312

Kontafarma China Delays Circular on Major Fitness Centre Lease Renewal

Kontafarma China Holdings Ltd ( ($HK:1312) ) has issued an announcement. Kontafarma China Holdings Limited has postponed the despatch of a shareholder circular relating to the renewal of a lease

2M ago1312

Kontafarma China Sets August Board Meeting to Review Interim Results and Dividend

Kontafarma China Holdings Ltd ( ($HK:1312) ) has provided an announcement. Kontafarma China Holdings Limited, incorporated in the Cayman Islands and listed in Hong Kong, is guided by a seven-member

2M ago1312

Kontafarma Flags Smaller First-Half Loss Amid Fresh Singapore Fitness Impairments

Kontafarma China Holdings Ltd ( ($HK:1312) ) has provided an announcement. Kontafarma China Holdings has warned that it expects to post a consolidated net loss of between HK$67.2 million and

2M ago1312

Kontafarma China Renews Major Lease for Fitness and Yoga Centre

Kontafarma China Holdings Ltd ( ($HK:1312) ) has shared an announcement. Kontafarma China Holdings Ltd, through its indirect non-wholly owned subsidiary True Yoga Pte. Ltd., operates a fitness and yoga

3M ago1312

1312 FAQ

What was Kontafarma China Holdings Ltd’s price range in the past 12 months?

Kontafarma China Holdings Ltd lowest stock price was HK$0.02 and its highest was HK$0.04 in the past 12 months.

What is Kontafarma China Holdings Ltd’s market cap?

Kontafarma China Holdings Ltd’s market cap is HK$156.20M.

When is Kontafarma China Holdings Ltd’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Kontafarma China Holdings Ltd’s earnings last quarter?

Kontafarma China Holdings Ltd released its earnings results on Aug 28, 2026. The company reported -HK$0.012 earnings per share for the quarter.

Is Kontafarma China Holdings Ltd overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Kontafarma China Holdings Ltd pay dividends?

Kontafarma China Holdings Ltd pays an annual dividend of HK$0.004 which represents an annual dividend yield of ―. See more information on Kontafarma China Holdings Ltd dividends here

What is Kontafarma China Holdings Ltd’s EPS estimate?

Kontafarma China Holdings Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kontafarma China Holdings Ltd have?

Kontafarma China Holdings Ltd has 5,588,572,000 shares outstanding.

What happened to Kontafarma China Holdings Ltd’s price movement after its last earnings report?

Kontafarma China Holdings Ltd reported an EPS of -HK$0.012 in its last earnings report. Following the earnings report the stock price went up 3.125%.

Which hedge fund is a major shareholder of Kontafarma China Holdings Ltd?

Currently, no hedge funds are holding shares in HK:1312

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Kontafarma China Holdings Ltd Stock Smart Score

Neutral

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description